The SYNCHRONIZE-1 trial has shown significant weight loss and reduction in liver fat, with up to 16.6% mean weight loss and up to 63.1% reduction in liver fat after 76 weeks.
Jaime Almandoz, MD, an endocrinologist, explores the findings of the trial, noting that the reduction in visceral fat is a key aspect of the weight loss.
The sub-study data showed up to 34% reduction in visceral fat after 76 weeks.
Almandoz highlights that the concept of weight loss quality is increasingly important to both clinicians and patients, explaining that visceral and ectopic fat are the specific adipose depots most strongly linked to insulin resistance, cardiometabolic risk, and progression of liver disease.
He notes that the reduction in visceral fat is not just a metabolic marker but a signal that the therapy is meaningfully disrupting the biological drivers of disease.
The MRI sub-study demonstrated meaningful reductions in visceral and liver fat alongside relative preservation of lean mass.
Almandoz emphasizes that the visceral fat findings reinforce the importance of measuring beyond BMI in clinical practice, advocating for routine waist circumference and waist-to-height ratio assessments to better identify patients with early disease detection who are at high cardiometabolic risk.
For instance, a 34% reduction in visceral fat can be a significant indicator of the therapy’s effectiveness in disrupting the biological drivers of disease.
The clinical implications of these findings are significant, as they suggest that the therapy may have a positive impact on patients’ overall health.
It is a signal that the therapy is working.
They are exploring the findings of the trial, noting that the reduction in visceral fat is a key aspect of the weight loss.
The reduction in liver fat is also an important aspect of the trial’s findings.
Jaime Almandoz, MD, emphasizes that the visceral fat findings reinforce the importance of measuring beyond BMI in clinical practice.
Measuring waist circumference and waist-to-height ratio can help clinicians better identify patients who are at high cardiometabolic risk.
The MRI sub-study demonstrated meaningful reductions in visceral and liver fat alongside relative preservation of lean mass, which is an important consideration in the treatment of patients with high cardiometabolic risk.
The therapy’s effectiveness in disrupting the biological drivers of disease is a key aspect of its potential benefits.
The trial’s findings have significant implications for the treatment of patients with high cardiometabolic risk.
Jaime Almandoz, MD, notes that the reduction in visceral fat is not just a metabolic marker but a signal that the therapy is meaningfully disrupting the biological drivers of disease.
The importance of measuring beyond BMI in clinical practice cannot be overstated.
Visceral and ectopic fat are the specific adipose depots most strongly linked to insulin resistance, cardiometabolic risk, and progression of liver disease.
The therapy’s potential benefits are significant, and its effectiveness in disrupting the biological drivers of disease is a key aspect of its potential benefits.
The clinical implications of these findings are significant, as they suggest that the therapy may have a positive impact on patients’ overall health.
Almandoz emphasizes that the visceral fat findings reinforce the importance of measuring beyond BMI in clinical practice.
